UT Partnership and IPF Catalyst

12 days ago

Mike Castana

"Yeah, so I think when you look back, one of the key decisions we made back in 2018 was to license Taibaso DPI to United Therapeutics. At that point we were in a cash crunch. The board said, "Hey, you can't keep spending money on R&D on a Fresa. You got to pick something." And so we ran two trials. One was a phase one on Taibaso and one was a four-week study on a Fresa. And if you ask me, both were home runs. It was the first time in a hundred years that a meal time insulin beat another meal time insulin in a head-to-head trial. On Taibaso we showed we could dose three times higher than United Therapeutics could with tolerability and safety and so that turned into a licensing deal that provided a royalty stream which today is basically what our market cap is."

The CEO discusses a pivotal 2018 licensing decision with United Therapeutics that rescued the company during a cash crunch. The successful head-to-head trial not only validated their technology but also created a sustainable royalty stream, forming a key catalyst for future upside—especially as they advance their IPF program.

Related Stocks